New generation BCG vaccines

Birkhauser Advances in Infectious Diseases

Volumn , Issue , 2011, Pages 119-169

  Tullius, Michael V ^a   Horwitz, Marcus A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

19 KDA LIPOPROTEIN; 30 KDA PROTEIN; 38 KDA GLYCOPROTEIN; ANTIGEN 85A; ANTIGEN 85B; BACTERIAL PROTEIN; BCG VACCINE; CATHEPSIN S; CYTOKINE; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; GLYCOPROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; LIPOPROTEIN; LIVE VACCINE; MYCOBACTERIUM ANTIGEN; PEPTIDE; PROTEIN 72F; PROTEIN MPB51; PROTEIN MPT64; PROTEIN MTB8.4; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; WAG 533;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BACTERIAL STRAIN; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG QUALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENDEMIC DISEASE; HELMINTH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOMODULATION; INCIDENCE; LUNG TUBERCULOSIS; MALNUTRITION; MORTALITY; MYCOBACTERIUM BOVIS; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PARASITOSIS; PHAGOSOME; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TUBERCULOSIS; VACCINE PRODUCTION;

EID: 79960049938     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-0346-0277-8_6     Document Type: Article

References (179)

1. Clemens DL, Horwitz MA (1995) Characterization of the Mycobacterium tuberculosis phagosome and evidence that phagosomal maturation is inhibited. J Exp Med 181:257-270
2. Armstrong JA, Hart PD (1971) Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J Exp Med 134:713-740
3. Crowle AJ, Dahl R, Ross E, May MH (1991) Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic. Infect Immun 59:1823-1831
4. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, Bennett LT, Bansal GP, Young JF, Lee MH, Hatfull GF et al. (1991) New use of BCG for recombinant vaccines. Nature 351:456-460
5. Stover CK, Bansal GP, Hanson MS, Burlein JE, Palaszynski SR, Young JF, Koenig S, Young DB, Sadziene A, Barbour AG (1993) Protective immunity elicited by recombinant bacilli Calmette- Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J Exp Med 178:197-209
6. Fuerst TR, Stover CK, de la Cruz VF (1991) Development of BCG as a live recombinant vector system: potential use as an HIV vaccine. Biotechnol Ther 2:159-178
7. Fuerst TR, de la Cruz VF, Bansal GP, Stover CK (1992) Development and analysis of recombinant BCG vector systems. AIDS Res Hum Retroviruses 8:1451-1455
8. Aldovini A, Young RA (1991) Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 351:479-482
9. Winter N, Lagranderie M, Rauzier J, Timm J, Leclerc C, Guy B, Kieny MP, Gheorghiu M, Gicquel B (1991) Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein. Gene 109:47-54
10. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S (2000) Recombinant bacillus Calmette- Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretoryprotein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 97:13853-13858
11. Youmans GP (1979) Tuberculosis. W.B. Saunders, Philadelphia
12. Brosch R, Gordon SV, Garnier T, Eiglmeier K, Frigui W, Valenti P, Dos Santos S, Duthoy S, Lacroix C, Garcia-Pelayo C et al (2007) Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA 104:5596-5601
13. Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, Rane S, Small PM (1999) Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284:1520-1523
14. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698-702
15. Rodrigues LC, Diwan VK, Wheeler JG (1993) Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 22:1154-1158
16. Fine PE (1989) The BCG story: lessons from the past and implications for the future. Rev Infect Dis 11(Suppl 2):S353-S359
17. World Health Organization (2009) Global tuberculosis control: epidemiology, strategy, financing, WHO/HTM/TB/2009.411. World Health Organization (http://www.who.int/)
18. Brandt L, Feino Cunha J, Weinreich Olsen A, Chilima B, Hirsch P, Appelberg R, Andersen P (2002) Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 70:672-678
19. Demangel C, Garnier T, Rosenkrands I, Cole ST (2005) Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens. Infect Immun 73:2190-2196
20. McMurray DN, Carlomagno MA, Mintzer CL, Tetzlaff CL (1985) Mycobacterium bovis BCG vaccine fails to protect protein-deficient guinea pigs against respiratory challenge with virulent Mycobacterium tuberculosis. Infect Immun 50:555-559
21. Behr MA, Small PM (1997) Has BCG attenuated to impotence? Nature 389:133-134
22. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S (2009) Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis. Vaccine 27:441-445
23. Hart PD, Sutherland I (1977) BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med J 2:293-295
24. Elias D, Akuffo H, Britton S (2006) Helminthes could influence the outcome of vaccines against TB in the tropics. Parasite Immunol 28:507-513
25. Rook GA, Dheda K, Zumla A (2005) Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat Rev Immunol 5:661-667
26. van der Wel N, Hava D, Houben D, Fluitsma D, van Zon M, Pierson J, Brenner M, Peters PJ (2007) M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 129:1287-1298
27. Harth G, Lee BY, Horwitz MA (1997) High-level heterologous expression and secretion in rapidly growing nonpathogenic mycobacteria of four major Mycobacterium tuberculosis extracellular proteins considered to be leading vaccine candidates and drug targets. Infect Immun 65:2321-2328
28. Horwitz MA, Harth G (2003) A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 71:1672-1679
29. Blander SJ, Horwitz MA (1989) Vaccination with the major secretory protein of Legionella pneumophila induces cell-mediated and protective immunity in a guinea pig model of Legionnaires' disease. J Exp Med 169:691-705
30. Blander SJ, Horwitz MA (1991) Vaccination with the major secretory protein of Legionella induces humoral and cell-mediated immune responses and protective immunity acrossdifferent serogroups of Legionella pneumophila and different species of Legionella. J Immunol 147:285-291
31. Blander SJ, Horwitz MA (1993) Major cytoplasmic membrane protein of Legionella pneumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires' disease. J Clin Invest 91:717-723
32. Pal PG, Horwitz MA (1992) Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity ina guinea pig model of pulmonary tuberculosis. Infect Immun 60:4781-4792
33. Horwitz MA, Lee BW, Dillon BJ, Harth G (1995) Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci USA 92:1530-1534
34. Horwitz MA (2005) Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. Microbes Infect 7:947-954
35. Wiker HG, Harboe M (1992) The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev 56:648-661
36. Lee BY, Horwitz MA (1995) Identification of macrophage and stress-induced proteins of Mycobacterium tuberculosis. J Clin Invest 96:245-249
37. Garbe TR, Barathi J, Barnini S, Zhang Y, Abou-Zeid C, Tang D, Mukherjee R, Young DB (1994) Transformation of mycobacterial species using hygromycin resistance as selectable marker. Microbiology 140(1):133-138
38. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S (2006) Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity. Vaccine 24:443-451
39. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S (2006) A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG. Vaccine 24:1593-1600
40. Gillis T, Harth G, Horwitz MA (2008) Recombinant BCG expressing Mycobacterium leprae or Mycobacterium tuberculosis Ag85B induce protection against M. leprae challenge comparable or superior to BCG: 17th International Leprosy Congress, Hyderabad (Andhra Pradesh), India
41. Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, Soler JH, Weichold F, Geiter L, Sadoff JC, Horwitz MA (2008) A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 198:1491-1501
42. Sugawara I, Udagawa T, Taniyama T (2007) Protective efficacy of recombinant (Ag85A) BCG Tokyo with Ag85A peptide boosting against Mycobacterium tuberculosis-infected guinea pigs in comparison with that of DNA vaccine encoding Ag85A. Tuberculosis (Edinb) 87:94-101
43. Sugawara I, Li Z, Sun L, Udagawa T, Taniyama T (2007) Recombinant BCG Tokyo (Ag85A) protects cynomolgus monkeys (Macaca fascicularis) infected with H37Rv Mycobacterium tuberculosis. Tuberculosis (Edinb) 87:518-525
44. Sugawara I, Sun L, Mizuno S, Taniyama T (2009) Protective efficacy of recombinant BCG Tokyo (Ag85A) in rhesus monkeys (Macaca mulatta) infected intratracheally with H37Rv Mycobacterium tuberculosis. Tuberculosis (Edinb) 89:62-67
45. Walsh GP, Tan EV, Dela Cruz EC, Abalos RM, Villahermosa LG, Young LJ, Cellona RV, Nazareno JB, Horwitz MA (1996) The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat Med 2:430-436
46. Jain R, Dey B, Dhar N, Rao V, Singh R, Gupta UD, Katoch VM, Ramanathan VD, Tyagi AK (2008) Enhanced and enduring protection against tuberculosis by recombinant BCG Ag85C and its association with modulation of cytokine profile in lung. PLoS ONE 3:e3869
47. Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A, Griffiths KE, Marchal G, Leclerc C, Cole ST (2003) Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 9:533-539
48. Pym AS, Brodin P, Brosch R, Huerre M, Cole ST (2002) Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol 46:709-717
49. Brodin P, Majlessi L, Brosch R, Smith D, Bancroft G, Clark S, Williams A, Leclerc C, Cole ST (2004) Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. J Infect Dis 190:115-122
50. Bao L, Chen W, Zhang H, Wang X (2003) Virulence, immunogenicity, and protectiveefficacy of two recombinant Mycobacterium bovis bacillus Calmette-Guerin strains expressingthe antigen ESAT-6 from Mycobacterium tuberculosis. Infect Immun 71:1656-1661
51. Castanon-Arreola M, Lopez-Vidal Y, Espitia-Pinzon C, Hernandez-Pando R (2005) A new vaccine against tuberculosis shows greater protection in a mouse model with progressive pulmonary tuberculosis. Tuberculosis (Edinb) 85:115-126
52. Rao V, Dhar N, Shakila H, Singh R, Khera A, Jain R, Naseema M, Paramasivan CN, Narayanan PR, Ramanathan VD et al (2005) Increased expression of Mycobacterium tuberculosis 19 kDa lipoprotein obliterates the protective efficacy of BCG by polarizing host immune responses to the Th2 subtype. Scand J Immunol 61:410-417
53. Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, Kuwayama S, Muraki Y, Kanamaru N, Hashimoto S, Takai H et al (2005) Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine 23:2132-2135
54. Shi C, Wang X, Zhang H, Xu Z, Li Y, Yuan L (2007) Immune responses and protective efficacy induced by 85B antigen and early secreted antigenic target-6 kDa antigen fusion protein secreted by recombinant bacille Calmette-Guerin. Acta Biochim Biophys Sin (Shanghai) 39:290-296
55. Xu Y, Zhu B, Wang Q, Chen J, Qie Y, Wang J, Wang H, Wang B (2007) Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice. FEMS Immunol Med Microbiol 51:480-487
56. Qie YQ, Wang JL, Liu W, Shen H, Chen JZ, Zhu BD, Xu Y, Zhang XL, Wang HH (2009) More vaccine efficacy studies on the recombinant Bacille Calmette-Guerin co expressing Ag85B, Mpt64 and Mtb8.4. Scand J Immunol 69:342-350
57. Ohara N, Matsuoka M, Nomaguchi H, Naito M, Yamada T (2001) Protective responses against experimental Mycobacterium leprae infection in mice induced by recombinantBacillus Calmette-Guerin over-producing three putative protective antigen candidates. Vaccine 19:1906-1910
58. Steele JH (1995) Regional and country status reports. Part 2. Introduction. In: Thoen CO, Steele JH (eds) Mycobacterium bovis infection in animals and humans. Iowa State University press, Ames, IA, pp 169-172
59. Hewinson RG, Vordermeier HM, Buddle BM (2003) Use of the bovine model of tuberculosis for the development of improved vaccines and diagnostics. Tuberculosis (Edinb) 83:119-130
60. Collins DM, de Lisle GW, Aldwell FE, Buddle BM (2007) A new attenuated Mycobacterium bovis vaccine protects brushtail possums (Trichosurus vulpecula) against experimental tuberculosis infection. Vaccine 25:4659-4664
61. World Health Organization (2007) Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec 82:193-196
62. Tullius MV, Harth G, Maslesa-Galic S, Dillon BJ, Horwitz MA (2008) A replication limited recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG. Infect Immun 76:5200-5214
63. Murray PJ, Aldovini A, Young RA (1996) Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc Natl Acad Sci USA 93:934-939
64. O'Donnell MA, Aldovini A, Duda RB, Yang H, Szilvasi A, Young RA, DeWolf WC (1994) Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 62:2508-2514
65. Ryan AA, Wozniak TM, Shklovskaya E, O'Donnell MA, de St F, Groth B, Britton WJ, Triccas JA (2007) Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs. J Immunol 179:8418-8424
66. Young SL, O'Donnell MA, Buchan GS (2002) IL-2-secreting recombinant bacillus Calmette Guerin can overcome a Type 2 immune response and corticosteroid-induced immunosuppression to elicit a Type 1 immune response. Int Immunol 14:793-800
67. Young S, O'Donnell M, Lockhart E, Buddle B, Slobbe L, Luo Y, De Lisle G, Buchan G (2002) Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guerin. Immunol Cell Biol 80:209-215
68. Slobbe L, Lockhart E, O'Donnell MA, MacKintosh C, De Lisle G, Buchan G (1999) An in vivo comparison of bacillus Calmette-Guerin (BCG) and cytokine-secreting BCG vaccines. Immunology 96:517-523
69. Tang C, Yamada H, Shibata K, Maeda N, Yoshida S, Wajjwalku W, Ohara N, Yamada T, Kinoshita T, Yoshikai Y (2008) Efficacy of recombinant bacille Calmette-Guerin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis. J Infect Dis 197:1263-1274
70. Arnold J, de Boer EC, O'Donnell MA, Bohle A, Brandau S (2004) Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. J Immunother 27:116-123
71. Liu W, O'Donnell MA, Chen X, Han R, Luo Y (2009) Recombinant bacillus Calmette-Guerin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro. Cancer Immunol Immunother 58:1647-1655
72. Luo Y, Chen X, Han R, O'Donnell MA (2001) Recombinant bacille Calmette-Guerin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 123:264-270
73. Yamada H, Matsumoto S, Matsumoto T, Yamada T, Yamashita U (2000) Murine IL 2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. J Urol 164:526-531
74. Luo Y, Yamada H, Chen X, Ryan AA, Evanoff DP, Triccas JA, O'Donnell MA (2004) Recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin Exp Immunol 137:24-34
75. Biet F, Kremer L, Wolowczuk I, Delacre M, Locht C (2002) Mycobacterium bovis BCG producing interleukin-18 increases antigen-specific gamma interferon production in mice. Infect Immun 70:6549-6557
76. Biet F, Duez C, Kremer L, Marquillies P, Amniai L, Tonnel AB, Locht C, Pestel J (2005) Recombinant Mycobacterium bovis BCG producing IL-18 reduces IL-5 production and bronchoalveolar eosinophilia induced by an allergic reaction. Allergy 60:1065-1072
77. Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser Eddine A, Mann P, Goosmann C, Bandermann S, Smith D et al (2005) Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115:2472-2479
78. Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA, Hall GA, Huygen K, Ottenhoff TH, Franken KL, Andersen P et al (2005) Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) 85:29-38
79. Sendide K, Deghmane AE, Pechkovsky D, Av-Gay Y, Talal A, Hmama Z (2005) Mycobacterium bovis BCG attenuates surface expression of mature class II molecules through IL-10-dependent inhibition of cathepsin S. J Immunol 175:5324-5332
80. Soualhine H, Deghmane AE, Sun J, Mak K, Talal A, Av-Gay Y, Hmama Z (2007) Mycobacterium bovis bacillus Calmette-Guerin secreting active cathepsin S stimulates expression of mature MHC class II molecules and antigen presentation in human macrophages. J Immunol 179:5137-5145
81. Sun R, Skeiky YA, Izzo A, Dheenadhayalan V, Imam Z, Penn E, Stagliano K, Haddock S, Mueller S, Fulkerson J et al (2009) Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 27:4412-4423
82. Snapper SB, Lugosi L, Jekkel A, Melton RE, Kieser T, Bloom BR, Jacobs WR Jr (1988) Lysogeny and transformation in mycobacteria: stable expression of foreign genes. Proc Natl Acad Sci USA 85:6987-6991
83. Jacobs WR Jr, Snapper SB, Lugosi L, Jekkel A, Melton RE, Kieser T, Bloom BR (1989) Development of genetic systems for the mycobacteria. Acta Leprol 7(Suppl 1):203-207
84. Jacobs WR Jr, Tuckman M, Bloom BR (1987) Introduction of foreign DNA into mycobacteria using a shuttle phasmid. Nature 327:532-535
85. Lugosi L, Jacobs W, Bloom BR (1989) Transformation of BCG with plasmid DNA. Acta Leprol 7(Suppl 1):256-257
86. Matsuo K, Yamaguchi R, Yamazaki A, Tasaka H, Terasaka K, Totsuka M, Kobayashi K, Yukitake H, Yamada T (1990) Establishment of a foreign antigen secretion systemin mycobacteria. Infect Immun 58:4049-4054
87. Yasutomi Y, Koenig S, Haun SS, Stover CK, Jackson RK, Conard P, Conley AJ, Emini EA, Fuerst TR, Letvin NL (1993) Immunization with recombinant BCG-SIV elicits SIV specific cytotoxic T lymphocytes in rhesus monkeys. J Immunol 150:3101-3107
88. Connell ND, Medina-Acosta E, McMaster WR, Bloom BR, Russell DG (1993) Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette Guerin expressing the Leishmania surface proteinase gp63. Proc Natl Acad Sci USA 90: 11473-11477
89. Haeseleer F, Pollet JF, Haumont M, Bollen A, Jacobs P (1993) Stable integration and expression of the Plasmodium falciparum circumsporozoite protein coding sequence in mycobacteria. Mol Biochem Parasitol 57:117-126
90. Cirillo JD, Stover CK, Bloom BR, Jacobs WR Jr, Barletta RG (1995) Bacterial vaccine vectors and bacillus Calmette-Guerin. Clin Infect Dis 20:1001-1009
91. Im EJ, Saubi N, Virgili G, Sander C, Teoh D, Gatell JM, McShane H, Joseph J, Hanke T (2007) Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J Virol 81:9408-9418
92. Leung NJ, Aldovini A, Young R, Jarvis MA, Smith JM, Meyer D, Anderson DE, Carlos MP, Gardner MB, Torres JV (2000) The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins. Virology 268:94-103
93. Lagranderie M, Winter N, Balazuc AM, Gicquel B, Gheorghiu M (1998) A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. AIDS Res Hum Retroviruses 14:1625-1633
94. Mederle I, Le Grand R, Vaslin B, Badell E, Vingert B, Dormont D, Gicquel B, Winter N (2003) Mucosal administration of three recombinant Mycobacterium bovis BCG SIVmac251 strains to cynomolgus macaques induces rectal IgAs and boosts systemic cellular immune responses that are primed by intradermal vaccination. Vaccine 21:4153-4166
95. Mederle I, Bourguin I, Ensergueix D, Badell E, Moniz-Peireira J, Gicquel B, Winter N (2002) Plasmidic versus insertional cloning of heterologous genes in Mycobacterium bovis BCG: impact on in vivo antigen persistence and immune responses. Infect Immun 70:303-314
96. Cayabyab M J, Korioth-Schmitz B, Sun Y, Carville A, Balachandran H, Miura A, Carlson KR, Buzby AP, Haynes BF, Jacobs WR et al (2009) Recombinant Mycobacterium bovis BCGprime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. J Virol 83:5505-5513
97. Wada N, Ohara N, Kameoka M, Nishino Y, Matsumoto S, Nishiyama T, Naito M, Yukitake H, Okada Y, Ikuta K et al (1996) Long-lasting immune response induced by recombinant bacillus Calmette-Guerin (BCG) secretion system. Scand J Immunol 43:202-209
98. Chege GK, Thomas R, Shephard EG, Meyers A, Bourn W, Williamson C, Maclean J, Gray CM, Rybicki EP, Williamson AL (2009) A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons. Vaccine 27:4857-4866
99. Kanekiyo M, Matsuo K, Hamatake M, Hamano T, Ohsu T, Matsumoto S, Yamada T, Yamazaki S, Hasegawa A, Yamamoto N et al (2005) Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis bacille Calmette-Guerin expressing human immunodeficiency virus type 1 Gag. J Virol 79:8716-8723
100. Promkhatkaew D, Matsuo K, Pinyosukhee N, Thongdeejaroen W, Leang-Aramgul P, Sawanpanyalert P, Warachit P (2009) Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes. Southeast Asian J Trop Med Public Health 40:273-281
101. Promkhatkaew D, Pinyosukhee N, Thongdeejaroen W, Sutthent R, Sawanpanyalert P, Warachit P (2009) Enhancement of cell-mediated immune response in mice by whole HIV-1 gag in Mycobacterium bovis BCG as a live vaccine candidate. Southeast Asian J Trop Med Public Health 40:113-122
102. Yasutomi Y, Koenig S, Woods RM, Madsen J, Wassef NM, Alving CR, Klein HJ, Nolan TE, Boots LJ, Kessler JA et al (1995) A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J Virol 69:2279-2284
103. Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, Horibata S, Yoshino N, Sakai K, Shinohara K, Matsumoto S et al (2005) Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J Virol 79:12871-12879
104. Kawahara M (2008) Recombinant Mycobacterium bovis BCG vector system expressing SIV Gag protein stably and persistently induces antigen-specific humoral immune response concomitant with IFN gamma response, even at three years after immunization. Clin Immunol 129:492-498
105. Kawahara M, Matsuo K, Honda M (2006) Intradermal and oral immunization with recombinant Mycobacterium bovis BCG expressing the simian immunodeficiency virus Gag protein induces long-lasting, antigen-specific immune responses in guinea pigs. Clin Immunol 119:67-78
106. Kameoka M, Nishino Y, Matsuo K, Ohara N, Kimura T, Yamazaki A, Yamada T, Ikuta K (1994) Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop. Vaccine 12: 153-158
107. Honda M, Matsuo K, Nakasone T, Okamoto Y, Yoshizaki H, Kitamura K, Sugiura W, Watanabe K, Fukushima Y, Haga S et al (1995) Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc Natl Acad Sci USA 92:10693-10697
108. Hiroi T, Goto H, Someya K, Yanagita M, Honda M, Yamanaka N, Kiyono H (2001) HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions. J Immunol 167:5862-5867
109. Kawahara M, Hashimoto A, Toida I, Honda M (2002) Oral recombinant Mycobacterium bovis bacillus Calmette-Guerin expressing HIV-1 antigens as a freeze-dried vaccine induces long-term, HIV-specific mucosal and systemic immunity. Clin Immunol 105:326-331
110. Kawahara M, Matsuo K, Nakasone T, Hiroi T, Kiyono H, Matsumoto S, Yamada T, Yamamoto N, Honda M (2002) Combined intrarectal/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen. Vaccine 21:158-166
111. Someya K, Cecilia D, Ami Y, Nakasone T, Matsuo K, Burda S, Yamamoto H, Yoshino N, Kaizu M, Ando S et al (2005) Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guerin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. J Virol 79:1452-1462
112. Aravindhan V, Narayanan S, Gautham N, Prasad V, Kannan P, Jacobs WR Jr, Narayanan P (2006) T-h-2 immunity and CD3{thorn}CD45RBlow-activated T cells in mice immunized with recombinant bacillus Calmette-Guerin expressing HIV-1 principal neutralizing determinant epitope. FEMS Immunol Med Microbiol 47:45-55
113. Chujoh Y, Matsuo K, Yoshizaki H, Nakasatomi T, Someya K, Okamoto Y, Naganawa S, Haga S, Yoshikura H, Yamazaki A et al (2001) Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B' strains by recombinant Mycobacterium bovis BCG-based candidate vaccine. Vaccine 20:797-804
114. Yu JS, Peacock JW, Jacobs WR Jr, Frothingham R, Letvin NL, Liao HX, Haynes BF (2007) Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites. Clin Vaccine Immunol 14:886-893
115. Lim EM, Lagranderie M, Le Grand R, Rauzier J, Gheorghiu M, Gicquel B, Winter N (1997) Recombinant Mycobacterium bovis BCG producing the N-terminal half of SIVmac251 Env antigen induces neutralizing antibodies and cytotoxic T lymphocyte responses in mice and guinea pigs. AIDS Res Hum Retroviruses 13:1573-1581
116. Gheorghiu M, Lagranderie MR, Gicquel BM, Leclerc CD (1994) Mycobacterium bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen. Infect Immun 62:4287-4295
117. Winter N, Lagranderie M, Gangloff S, Leclerc C, Gheorghiu M, Gicquel B (1995) Recombinant BCG strains expressing the SIVmac251nef gene induce proliferative and CTL responses against nef synthetic peptides in mice. Vaccine 13:471-478
118. Lagranderie M, Balazuc AM, Gicquel B, Gheorghiu M (1997) Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local and systemic cytotoxic T-lymphocyte responses in mice. J Virol 71:2303-2309
119. Fennelly GJ, Flynn JL, Ter Meulen V, Liebert UG, Bloom BR (1995) Recombinant bacilli Calmette-Guerin priming against measles. J Infect Dis 172:698-705
120. Zhu YD, Fennelly G, Miller C, Tarara R, Saxe I, Bloom B, McChesney M (1997) Recombinant bacille Calmette-Guerin expressing the measles virus nucleoprotein protects infant rhesus macaques from measles virus pneumonia. J Infect Dis 176:1445-1453
121. Jabbar IA, Fernando GJ, Saunders N, Aldovini A, Young R, Malcolm K, Frazer IH (2000) Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 18:2444-2453
122. Govan VA, Christensen ND, Berkower C, Jacobs WR Jr, Williamson AL (2006) Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge. Vaccine 24:2087-2093
123. Govan VA, Williamson AL (2007) Rabbits immunised with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L2E7E2 genes induces regression of established papillomas. Virus Res 127:43-48
124. Bastos RG, Dellagostin OA, Barletta RG, Doster AR, Nelson E, Osorio FA (2002) Construction and immunogenicity of recombinant Mycobacterium bovis BCG expressing GP5 and M protein of porcine reproductive respiratory syndrome virus. Vaccine 21:21-29
125. Bastos RG, Dellagostin OA, Barletta RG, Doster AR, Nelson E, Zuckermann F, Osorio FA (2004) Immune response of pigs inoculated with Mycobacterium bovis BCG expressing a truncated form of GP5 and M protein of porcine reproductive and respiratory syndrome virus. Vaccine 22:467-474
126. Rezende CA, De Moraes MT, De Souza Matos DC, McIntoch D, Armoa GR (2005) Humoral response and genetic stability of recombinant BCG expressing hepatitis B surface antigens. J Virol Methods 125:1-9
127. Uno-Furuta S, Matsuo K, Tamaki S, Takamura S, Kamei A, Kuromatsu I, Kaito M, Matsuura Y, Miyamura T, Adachi Y et al (2003) Immunization with recombinant Calmette Guerin bacillus (BCG)-hepatitis C virus (HCV) elicits HCV-specific cytotoxic T lymphocytes in mice. Vaccine 21:3149-3156
128. Wei SH, Yin W, An QX, Lei YF, Hu XB, Yang J, Lu X, Zhang H, Xu ZK (2008) A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen. Arch Virol 153:1021-1029
129. Dennehy M, Bourn W, Steele D, Williamson AL (2007) Evaluation of recombinant BCG expressing rotavirus VP6 as an anti-rotavirus vaccine. Vaccine 25:3646-3657
130. Bueno SM, Gonzalez PA, Cautivo KM, Mora JE, Leiva ED, Tobar HE, Fennelly GJ, Eugenin EA, Jacobs WR Jr, Riedel CA et al (2008) Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc Natl Acad SciUSA 105:20822-20827
131. Choi BK, Cho SH, Bai GH, Kim SJ, Hyun BH, Choe YK, Bae YS (2000) Prevention ofencephalomyocarditis virus-induced diabetes by live recombinant Mycobacterium bovis bacillus Calmette-Guerin in susceptible mice. Diabetes 49:1459-1467
132. da Cruz FW, McBride AJ, Conceicao FR, Dale JW, McFadden J, Dellagostin OA (2001) Expression of the B-cell and T-cell epitopes of the rabies virus nucleoprotein inMycobacterium bovis BCG and induction of an humoral response in mice. Vaccine 20:731-736
133. Zheng C, Xie P, Chen Y (2002) Recombinant Mycobacterium bovis BCG producing the circumsporozoite protein of Plasmodium falciparum FCC-1/HN strain inducesstrong immune responses in BALB/c mice. Parasitol Int 51:1-7
134. Matsumoto S, Yanagi T, Ohara N, Wada N, Kanbara H, Yamada T (1996) Stableexpression and secretion of the B-cell epitope of rodent malaria from Mycobacterium bovis BCG and induction of long-lasting humoral response in mouse. Vaccine 14:54-60
135. Matsumoto S, Yukitake H, Kanbara H, Yamada T (1998) Recombinant Mycobacterium bovis bacillus Calmette-Guerin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies. J Exp Med 188:845-854
136. Matsumoto S, Yukitake H, Kanbara H, Yamada H, Kitamura A, Yamada T (2000) Mycobacterium bovis bacillus calmette-guerin induces protective immunity against infection by Plasmodium yoelii at blood-stage depending on shifting immunity toward Th1 type and inducing protective IgG2a after the parasite infection. Vaccine 19:779-787
137. Zheng C, Xie P, Chen Y (2001) Immune response induced by recombinant BCGexpressing merozoite surface antigen 2 from Plasmodium falciparum. Vaccine 20:914-919
138. Rapeah S, Norazmi MN (2006) Immunogenicity of a recombinant Mycobacterium bovis bacille Calmette-Guerin expressing malarial and tuberculosis epitopes. Vaccine 24:3646-3653
139. Abdelhak S, Louzir H, Timm J, Blel L, Benlasfar Z, Lagranderie M, Gheorghiu M, Dellagi K, Gicquel B (1995) Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice. Microbiology 141(Pt 7):1585-1592
140. Streit JA, Recker TJ, Donelson JE, Wilson ME (2000) BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice. Exp Parasitol 94:33-41
141. Kremer L, Baulard A, Estaquier J, Content J, Capron A, Locht C (1995) Analysis of the Mycobacterium tuberculosis 85A antigen promoter region. J Bacteriol 177:642-653
142. Kremer L, Riveau G, Baulard A, Capron A, Locht C (1996) Neutralizing antibody responses elicited in mice immunized with recombinant bacillus Calmette-Guerin producing the Schistosoma mansoni glutathione S-transferase. J Immunol 156:4309-4317
143. Kremer L, Dupre L, Riveau G, Capron A, Locht C (1998) Systemic and mucosal immune responses after intranasal administration of recombinant Mycobacterium bovis bacillus Calmette-Guerin expressing glutathione S-transferase from Schistosoma haematobium. Infect Immun 66:5669-5676
144. Dai W, Gao H, Huang H, Yuan Y, Hu J, Huangfu Y (2003) Comparative study on the immunogenicity between recombinant MS-Sj26GST vaccine and recombinant BCGSj26GST vaccine in Schistosoma japonicum. J Huazhong Univ Sci Technolog Med Sci 23 (213-215):218
145. Varaldo PB, Leite LC, Dias WO, Miyaji EN, Torres FI, Gebara VC, Armoa GR, Campos AS, Matos DC, Winter N et al (2004) Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge. Infect Immun 72:3336-3343
146. Varaldo PB, Miyaji EN, Vilar MM, Campos AS, Dias WO, Armoa GR, Tendler M, Leite LC, McIntosh D (2006) Mycobacterial codon optimization of the gene encoding the Sm14 antigen of Schistosoma mansoni in recombinant Mycobacterium bovis Bacille Calmette Guerin enhances protein expression but not protection against cercarial challenge in mice. FEMS Immunol Med Microbiol 48:132-139
147. Supply P, Sutton P, Coughlan SN, Bilo K, Saman E, Trees AJ, Cesbron Delauw MF, Locht C (1999) Immunogenicity of recombinant BCG producing the GRA1 antigen from Toxoplasma gondii. Vaccine 17:705-714
148. Wang H, Liu Q, Liu K, Zhong W, Gao S, Jiang L, An N (2007) Immune response induced by recombinant Mycobacterium bovis BCG expressing ROP2 gene of Toxoplasma gondii. Parasitol Int 56:263-268
149. Wang Q, Li J, Zhang X, Liu Q, Liu C, Ma G, Cao L, Gong P, Cai Y, Zhang G (2009) Protective immunity of recombinant Mycobacterium bovis BCG expressing rhomboid gene against Eimeria tenella challenge. Vet Parasitol 160:198-203
150. Langermann S, Palaszynski S, Sadziene A, Stover CK, Koenig S (1994) Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borreliaburgdorferi. Nature 372:552-555
151. Edelman R, Palmer K, Russ KG, Secrest HP, Becker JA, Bodison SA, Perry JG, Sills AR, Barbour AG, Luke CJ et al (1999) Safety and immunogenicity of recombinantBacille Calmette-Guerin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine 17:904-914
152. Miller LA, Johns BE, Elias DJ, Killian GJ (1999) Oral vaccination of white tailed deer using a recombinant Bacillus Calmette-Guerin vaccine expressing the Borrelia burgdorferi outer surface protein A: prospects for immunocontraception. Am J Reprod Immunol 41:279-285
153. Langermann S, Palaszynski SR, Burlein JE, Koenig S, Hanson MS, Briles DE, Stover CK (1994) Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guerin vaccines expressing pneumococcal surface protein A. J Exp Med 180:2277-2286
154. Seixas FK, da Silva EF, Hartwig DD, Cerqueira GM, Amaral M, Fagundes MQ, Dossa RG, Dellagostin OA (2007) Recombinant Mycobacterium bovis BCG expressing the LipL32 antigen of Leptospira interrogans protects hamsters from challenge. Vaccine 26:88-95
155. Seixas FK, Fernandes CH, Hartwig DD, Conceicao FR, Aleixo JA, Dellagostin OA (2007) Evaluation of different ways of presenting LipL32 to the immune system with the aim of developing a recombinant vaccine against leptospirosis. Can J Microbiol 53:472-479
156. Grode L, Kursar M, Fensterle J, Kaufmann SH, Hess J (2002) Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette-Guerin strains against an intracellular bacterial pathogen: importance of antigen secretion or membrane targeted antigen display as lipoprotein for vaccine efficacy. J Immunol 168:1869-1876
157. Abomoelak B, Huygen K, Kremer L, Turneer M, Locht C (1999) Humoral and cellular immune responses in mice immunized with recombinant Mycobacterium bovis Bacillus Calmette-Guerin producing a pertussis toxin-tetanus toxin hybrid protein. Infect Immun 67:5100-5105
158. Medeiros MA, Armoa GR, Dellagostin OA, McIntosh D (2005) Induction of humoral immunity in response to immunization with recombinant Mycobacterium bovis BCG expressing the S1 subunit of Bordetella pertussis toxin. Can J Microbiol 51:1015-1020
159. Nascimento IP, Dias WO, Mazzantini RP, Miyaji EN, Gamberini M, Quintilio W, Gebara VC, Cardoso DF, Ho PL, Raw I et al (2000) Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice. Infect Immun 68:4877-4883
160. Nascimento IP, Dias WO, Quintilio W, Christ AP, Moraes JF, Vancetto MD, Ribeiro- Dos-Santos G, Raw I, Leite LC (2008) Neonatal immunization with a single dose of recombinant BCG expressing subunit S1 from pertussis toxin induces complete protection against Bordetella pertussis intracerebral challenge. Microbes Infect 10:198-202
161. Miyaji EN, Mazzantini RP, Dias WO, Nascimento AL, Marcovistz R, Matos DS, Raw I, Winter N, Gicquel B, Rappuoli R et al (2001) Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant Mycobacterium bovis BCG expressing CRM (197), a mutant diphtheria toxin. Infect Immun 69:869-874
162. Mazzantini RP, Miyaji EN, Dias WO, Sakauchi D, Nascimento AL, Raw I, Winter N, Gicquel B, Rappuoli R, Leite LC (2004) Adjuvant activity of Mycobacterium bovis BCG expressing CRM197 on the immune response induced by BCG expressing tetanus toxin fragment C. Vaccine 22:740-746
163. Michelon A, Conceicao FR, Binsfeld PC, da Cunha CW, Moreira AN, Argondizzo AP, McIntosh D, Armoa GR, Campos AS, Farber M et al (2006) Immunogenicity of Mycobacterium bovis BCG expressing Anaplasma marginale MSP1a antigen. Vaccine 24:6332-6339
164. Biet F, Kremer L, Wolowczuk I, Delacre M, Locht C (2003) Immune response induced by recombinant Mycobacterium bovis BCG producing the cholera toxin B subunit. Infect Immun 71:2933-2937
165. Hayward CM, O'Gaora P, Young DB, Griffin GE, Thole J, Hirst TR, Castello Branco LR, Lewis DJ (1999) Construction and murine immunogenicity of recombinant Bacille Calmette Guerin vaccines expressing the B subunit of Escherichia coli heat labile enterotoxin. Vaccine 17:1272-1281
166. Da Silva Ramos Rocha A, Conceicao FR, Grassmann AA, Lagranha VL, Dellagostin OA (2008) B subunit of Escherichia coli heat-labile enterotoxin as adjuvant of humoral immune response in recombinant BCG vaccination. Can J Microbiol 54:677-686
167. Dudani R, Chapdelaine Y, Faassen Hv H, Smith DK, Shen H, Krishnan L, Sad S (2002) Multiple mechanisms compensate to enhance tumor-protective CD8({thorn}) T cell response in the long-term despite poor CD8({thorn}) T cell priming initially: comparison between an acute versus a chronic intracellular bacterium expressing a model antigen. J Immunol 168:5737-5745
168. Cheadle EJ, O'Donnell D, Selby PJ, Jackson AM (2005) Closely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells. Infect Immun 73:784-794
169. He J, Shen D, O'DonnellMA, Chang HR (2002) Induction ofMUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2. Int J Oncol 20:1305-1311
170. Yuan S, Shi C, Han W, Ling R, Li N, Wang T (2009) Effective anti-tumor responses induced by recombinant bacillus Calmette-Guerin vaccines based on different tandem repeats of MUC1 and GM-CSF. Eur J Cancer Prev 18:416-423
171. Chade DC, Borra RC, Nascimento IP, Villanova FE, Leite LC, Andrade E, Srougi M, Ramos KL, Andrade PM (2008) Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model. J Exp Clin Cancer Res 27:78
172. Janssen R, Kruisselbrink A, Hoogteijling L, Lamb JR, Young DB, Thole JE (2001) Analysis of recombinant mycobacteria as T helper type 1 vaccines in an allergy challenge model. Immunology 102:441-449
173. Joseph J, Saubi N, Pezzat E, Gatell JM (2006) Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guerin: failures and challenges. Expert Rev Vaccines 5:827-838
174. Ohara N, Yamada T (2001) Recombinant BCG vaccines. Vaccine 19:4089-4098
175. Dennehy M, Williamson AL (2005) Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines. Vaccine 23:1209-1224
176. Bastos RG, Borsuk S, Seixas FK, Dellagostin OA (2009) Recombinant Mycobacterium bovis BCG. Vaccine 27:6495-6503
177. Walker BD, Burton DR (2008) Toward an AIDS vaccine. Science 320:760-764
178. Barouch DH (2008) Challenges in the development of an HIV-1 vaccine. Nature 455:613-619
179. Hanke T, McMichael AJ (2000) Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 6:951-955